IFNA1 and COVID-19: Interestingly, several in vivo studies showed delayed and/or impaired type I (IFN-α and IFN-β) and type III (IFN-λ) interferon production in blood samples or nasopharyngeal swabs of COVID-19 patients particularly linked to the more severe manifestation of the disease [1,2,11,12,13].